[to top of second column]
Sebelius announced the FDA's approval of vaccine made by four of the expected five manufacturers: CSL Ltd. of Australia, Switzerland's Novartis Vaccines, Sanofi Pasteur of France -- which produces flu shots at its Swiftwater, Pa., factory -- and Maryland-based MedImmune LLC, which makes the only nasal-spray flu vaccine.
London-based GlaxoSmithKline also was expected to supply vaccine. Sebelius said only that a fifth manufacturer's vaccine was expected to be approved soon, pending some final steps.
Getting licensing from the FDA means that the vaccine is made properly and meets specific manufacturing and quality standards.
What's the right dose? Figuring that out is the job of the National Institutes of Health, which last week announced studies showing that one dose appears to protect adults -- and that protection kicks in just eight to 10 days after the shot, faster than scientists had predicted.
Studies in children and pregnant women are continuing to settle on the right dose for those populations.
The H1N1 vaccine seems just as safe as the long-used regular flu vaccine, the FDA said -- not a surprise as it's made the same way. Side effects include soreness or redness at the injection site, and some fever.
The government will keep a sharp eye for any very rare side effects. The last mass vaccination against a different swine flu, in 1976, was marred by reports of the paralyzing Guillain-Barre syndrome; scientists never proved whether that link was real or coincidence.
Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
< Recent articles
Back to top
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Law & Courts |
Spiritual Life |
Health & Fitness |
Calendar | Letters to the Editor